As we had demonstrated that AA treatment could decrease the levels of Bcl-2 in NSCLC cells, we further examined whether a reduction of Bcl-2 was caused by AMPK/mTOR-facilitating degradation of Bcl-2. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.